RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $5.29 Average Target Price from Analysts

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have been assigned an average recommendation of “Hold” from the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $5.29.

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of RAPT Therapeutics in a research report on Monday, March 10th.

Hedge Funds Weigh In On RAPT Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Picton Mahoney Asset Management lifted its stake in RAPT Therapeutics by 994.4% in the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock valued at $26,000 after buying an additional 14,697 shares in the last quarter. JPMorgan Chase & Co. raised its position in RAPT Therapeutics by 298.2% in the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after purchasing an additional 25,130 shares during the period. Readystate Asset Management LP purchased a new stake in RAPT Therapeutics in the 3rd quarter valued at about $36,000. Barclays PLC increased its holdings in RAPT Therapeutics by 277.2% in the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after purchasing an additional 29,195 shares during the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in RAPT Therapeutics during the fourth quarter worth $63,000. Institutional investors and hedge funds own 99.09% of the company’s stock.

RAPT Therapeutics Price Performance

NASDAQ RAPT opened at $1.31 on Thursday. RAPT Therapeutics has a 1 year low of $0.79 and a 1 year high of $9.65. The company has a fifty day moving average price of $1.17 and a 200-day moving average price of $1.48. The firm has a market cap of $172.93 million, a price-to-earnings ratio of -0.47 and a beta of -0.31.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.69). On average, research analysts anticipate that RAPT Therapeutics will post -2.14 EPS for the current fiscal year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.